Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/18/2024 | Outperform → Perform | Oppenheimer | |
| 4/30/2024 | $9.00 | Buy | B. Riley Securities |
| 4/29/2024 | $9.00 | Buy | H.C. Wainwright |
| 4/5/2024 | $8.00 | Outperform | Wedbush |
| 12/21/2023 | $11.00 | Buy | BTIG Research |
| 10/13/2023 | $8.00 | Outperform | Oppenheimer |
| 8/25/2021 | $4.50 → $4.00 | Neutral | Citigroup |
SC 13G/A - Ovid Therapeutics Inc. (0001636651) (Subject)
SC 13G/A - Ovid Therapeutics Inc. (0001636651) (Subject)
SC 13G/A - Ovid Therapeutics Inc. (0001636651) (Subject)
4 - Ovid Therapeutics Inc. (0001636651) (Issuer)
3 - Ovid Therapeutics Inc. (0001636651) (Issuer)
4 - Ovid Therapeutics Inc. (0001636651) (Issuer)
10-Q - Ovid Therapeutics Inc. (0001636651) (Filer)
8-K - Ovid Therapeutics Inc. (0001636651) (Filer)
8-K - Ovid Therapeutics Inc. (0001636651) (Filer)
Conference call at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We had a strong quarter and are on track to meet the long-term growth objectives we outlined in December," said Todd Davis, CEO of Ligand. "We added four new commercial-stage programs in the first half of this year, including QARZIBA®, an orphan oncology product we acquired following the APEIRON Biologics transacti
Oppenheimer downgraded Ovid Therapeutics from Outperform to Perform
B. Riley Securities initiated coverage of Ovid Therapeutics with a rating of Buy and set a new price target of $9.00
H.C. Wainwright initiated coverage of Ovid Therapeutics with a rating of Buy and set a new price target of $9.00
A Phase 1 SAD/MAD study of OV329 is progressing as planned, and based on encouraging human safety data to date, Ovid will engage regulators about adding cohorts to increase potential dosing opportunities for Phase 2 programs.A regulatory application for a Phase 1 trial of OV350, the first candidate from Ovid's KCC2 direct activator library, is expected to be filed in Q4 2024.The Company will host a KCC2 Download Day on November 13 to provide updates on Ovid's platform of KCC2 direct activators and their broad therapeutic potential.Ovid and Graviton are pausing the initiation of a Phase 2 study of OV888/GV101 to evaluate emerging insights from two recently completed competitor trials in cereb
NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today announced that it will host an investor event focused on its portfolio of direct potassium chloride co-transporter 2 (KCC2) activators on Wednesday, November 13, 2024. The event will take place at Ovid's headquarters in New York's Hudson Yards from 9:30 to 11:30 am ET and will be webcast simultaneously. The session will focus on the biological relevance and broad potential therapeutic opportunity associated with Ovid's KCC2 portfolio. Company management will provide updates on the po
Study found OV329 cleared and remained undetectable in the retina, eye, and brain tissues of mice, unlike vigabatrin which has repeatedly shown to preferentially accumulate in mouse retinas, eyes, and other tissues OV329's potency, mechanism of inhibition, short half-life, rapid tissue elimination and prolonged pharmacodynamic effect suggests it delivers a differentiated ocular safety and efficacy profile from vigabatrin A Phase 1 trial evaluating OV329 in healthy volunteers is on-track for completion in late 2024 and will evaluate safety and two biomarkers for target engagement and evidence of clinical effect NEW YORK, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:O
4 - Ovid Therapeutics Inc. (0001636651) (Issuer)
Sustained exposure to OV329 in preclinical models reduced GABA-aminotransferase (GABA-AT) activity, increased steady state GABA levels in the brain, and induced phasic and tonic inhibition OV329 demonstrated anti-convulsant effects in mice, reducing the severity of status epilepticus and preventing the development of benzodiazepine-resistant seizures OV329 was shown to have a higher potency (as measured by IC50) for the GABA-AT target than published studies of vigabatrin, an FDA-approved GABA-AT inhibitor NEW YORK, July 10, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brai
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Ovid Therapeutics (NASDAQ:OVID) with a Buy and maintains $3 price target.
The Phase 1 study for OV888/GV101 capsule met its objective, demonstrating a favorable safety and tolerability profile with no serious adverse eventsSecondary endpoint results indicate that the target pharmacokinetic profile was achieved at the targeted clinical dose, supporting once daily dosingOV888/GV101 capsule was shown to be biologically active in participants and elicited dose-dependent pharmacodynamic effects within the planned therapeutic dose rangeA Phase 2 study for the treatment of cerebral cavernous malformations is expected to initiate in the second half of 2024
NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today announced the appointment of Amanda Banks, M.D., as Chief Development Officer. Dr. Banks will oversee Ovid's clinical development, medical, and regulatory affairs functions as well as drive corporate development strategy and execution in partnership with the Company's leadership team. Dr. Banks brings to Ovid broad and deep experience in neurology, clinical strategy, and business development. Her strategic acumen will serve Ovid at an important juncture for the Company as it determ
Neurologists/epileptologists Dr. Imad Najm of the Cleveland Clinic Neurological Institute and the Cleveland Clinic Epilepsy Center, and Dr. Raman Sankar, the Emeritus Chief of Pediatric Neurology at UCLA Health, appointed to Ovid's Scientific Advisory Board (SAB)Neuroscientists Dr. Jamie Maguire of Tufts University and Dr. Jeff Noebels of Baylor College of Medicine, appointed to the SAB to contribute expertise in neurophysiology, hyperexcitability and network effectsThe SAB will advise on the potential application of Ovid's compounds to broader disorders in which they may offer therapeutic promise, including brain conditions caused by hyperexcitability, neurovascular and neuro-inflammatory d
Dr. Zhong Zhong joins Ovid as Chief Scientific Officer (CSO) and Dr. Manoj Malhotra assumes role as Chief Medical Officer (CMO) following the planned retirement of Dr. Claude NicaiseMeg Alexander promoted to Chief Strategy OfficerOvid streamlined G&A infrastructure to improve operational efficiency and reduce costs NEW YORK, June 28, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare epilepsies and seizure-related disorders, today announced leadership appointments intended to enhance the execution of its corporate strategy and the scientific stewardship of its therapeutic